Using TRAP to Evaluate the Effect of Zometa on Bone Metastasis Due to Lung Cancer

Stopped early · Phase 2

Conditions studied: Carcinoma, Non-Small Cell Lung, Carcinoma, Small Cell Lung, Metastases

In brief

The purpose of this study is to evaluate a new blood test as a way to follow the effect of Zometa in treating bone metastases due to lung cancer.

Key facts

Study ID

NCT00265200

Run by

University of Louisville

People needed

28

Starts

2005-02-01

Expected to finish

2010-12-01

Last updated by the study team

2018-03-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• invasive lung cancer (small cell or non-small cell lung cancer)
• osteolytic bone metastasis determined by clinical exam, bone scan/XR
• age > 18 years

You may not qualify if…

• concurrent malignancy with a second primary
• renal failure (serum creatinine > 3mg/dl)
• pregnancy
• active rheumatoid arthritis
• intolerance to zoledronic acid

Where it is running

• James Graham Brown Cancer Center — Louisville, Kentucky, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.